Zymeworks Inc logo

ZYME

Zymeworks Inc

$6.23

Earnings Summary

Net Profits
$-0.06Mn

Highlights

Net Profits:

Zymeworks Inc’s net profit jumped 99.92% since last year same period to $-0.06Mn in the Q2 2022. On a quarterly growth basis, Zymeworks Inc has generated 99.91% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Zymeworks Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.96
EPS Estimate Current Year
-0.96

Highlights

EPS Estimate Current Quarter:

Zymeworks Inc’s earning per share (EPS) estimates for the current quarter stand at -0.96 - a 42.51% jump from last quarter’s estimates.

EPS Estimate Current Year:

Zymeworks Inc’s earning per share (EPS) estimates for the current year stand at -0.96.

Key Ratios

Key ratios of the Zymeworks Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.29
Return on Equity (ROE)
-0.64
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Zymeworks Inc’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Zymeworks Inc’s return on equity (ROE) stands at -0.64.

Dividend Per Share (DPS):

Zymeworks Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-1.67
-1.18
29.34%

Company Information

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.

Organisation
Zymeworks Inc
Headquarters
Vancouver, British Columbia, Canada
Employees
354
Industry
Health Technology
CEO
Ali Tehrani